Table 3.
Univariable and multivariable Cox regression analyses of potential prognostic variables for EC patients.
| Variables | Entire EC cohort |
Test EC cohort |
|||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Univariable analysis | |||||
| Age | >60 vs. ≤60 | 2.27 (1.25–4.15) | 0.007 | 2.18 (0.46–0.73) | 0.16 |
| FIGO stage | Advanced stage vs. Early stage | 4.55 (2.83–7.31) | ###### | 4.89 (2.04–11.68) | ###### |
| Histologic grade | G3 vs. G1/G2 | 3.61 (1.85–7.05) | ###### | 5.16 (1.20–22.19) | 0.03 |
| Histological type | MSE vs. EEA | 2.36 (0.92–6.04) | 0.07 | 5.50 (1.45–20.83) | 0.01 |
| SEA vs. EEA | 3.13 (1.93–5.08) | ###### | 5.14 (2.00–13.24) | ###### | |
| Methylation model | High risk vs. low risk | 11.31 (6.27–20.38) | ###### | 18.00 (6.00–54.00) | ###### |
| Multivariable analysis | |||||
| Age | >60 vs. ≤60 | 1.41 (0.75–2.63) | 0.28 | 0.78 (0.22–2.77) | 0.70 |
| FIGO stage | Advanced stage vs. Early stage | 3.13 (1.90–5.18) | ###### | 5.31 (1.78–15.89) | ###### |
| Histologic grade | G3 vs. G1/G2 | 1.37 (0.64–2.90) | ###### | 2.18 (0.43–10.99) | 0.34 |
| Histological type | MSE vs. EEA | 1.04 (0.39–2.76) | 0.94 | 1.82 (0.38–8.66) | 0.45 |
| SEA vs. EEA | 0.76 (0.43–1.35) | 0.35 | 0.41 (0.10–1.63) | 0.20 | |
| Methylation model | High risk vs. low risk | 8.78 (4.55–16.95) | ###### | 22.41 (5.58–89.98) | ###### |
Advanced stage: I/II stage; Early stage: III/IV stage; EEA: Endometrioid endometrial adenocarcinoma; MSE: Mixed serous and endometrioid; SEA: Serous endometrial adenocarcinoma.